Mar 20, 2019
Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019
Mar 14, 2019
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Feb 27, 2019
Eiger BioPharmaceuticals Announces the Appointment of Stephana Patton as General Counsel, Corporate Secretary, and Chief Compliance Officer
Dec 19, 2018
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
Dec 11, 2018
Eiger BioPharmaceuticals Reports on 2018 R&D Day
Dec 03, 2018
Eiger BioPharmaceuticals Announces the Appointment of Sri Ryali as Chief Financial Officer
Dec 03, 2018
Eiger BioPharmaceuticals Announces FDA Acceptance of IND Application for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies
Nov 19, 2018
Eiger to Participate in Piper Jaffray Healthcare Conference
Nov 09, 2018
Eiger Bio Reports Third Quarter 2018 Financial Results
Oct 22, 2018
Eiger BioPharmaceuticals Receives FDA Rare Pediatric Disease (RPD) Designation for Lonafarnib for the Treatment of Progeria and Progeroid Laminopathies and Plans NDA Filing in 2019
Oct 18, 2018
Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference
Oct 16, 2018
Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint
Sep 25, 2018
Eiger BioPharmaceuticals to Participate in Investor Conferences
Sep 04, 2018
Eiger Announces Positive Meeting with FDA on Progeria Program
Aug 10, 2018
Eiger BioPharmaceuticals Reports Second Quarter 2018 Financial Results
May 16, 2018
Eiger Announces Expanded License Agreement with Merck for Investigational Candidate Lonafarnib and Collaboration with The Progeria Research Foundation (PRF)
May 16, 2018
Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals